rss
Ann Rheum Dis 68:1613-1617 doi:10.1136/ard.2009.108936
  • Clinical and epidemiological research
  • Concise report

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

Open Access
  1. R Terkeltaub1,
  2. J S Sundy2,
  3. H R Schumacher3,
  4. F Murphy4,
  5. S Bookbinder5,
  6. S Biedermann6,
  7. R Wu6,
  8. S Mellis6,
  9. A Radin6
  1. 1
    VAMC/UCSD, San Diego, USA
  2. 2
    Rheumatology and Immunology, Duke University Medical Center, Durham, USA
  3. 3
    University of Pennsylvania, VAMC, Philadelphia, USA
  4. 4
    Altoona Center for Clinical Research, Duncansville, USA
  5. 5
    Ocala Rheumatology Research Center, Ocala, USA
  6. 6
    Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, USA
  1. Correspondence to Dr R Terkeltaub, VAMC Rheumatology, 111K, 3350 La Jolla Village Drive, San Diego, CA 92161; rterkeltaub{at}ucsd.edu
  • Accepted 26 June 2009
  • Published Online First 26 July 2009

Abstract

Background: Recent studies suggest that blockade of the NLRP3 (cryopyrin) inflammasome interleukin 1β (IL1β) pathway may offer a new treatment strategy for gout.

Objective: To explore the potential utility of rilonacept (IL1 Trap) in patients with chronic active gouty arthritis in a proof-of-concept study.

Methods: This 14-week, multicentre, non-randomised, single-blind, monosequence crossover study of 10 patients with chronic active gouty arthritis included a placebo run-in (2 weeks), active rilonacept treatment (6 weeks) and a 6-week post-treatment follow-up.

Results: Rilonacept was generally well tolerated. No deaths and no serious adverse events occurred during the study. One patient withdrew owing to an injection-site reaction. Patients’ self-reported median pain visual analogue scale scores significantly decreased from week 2 (after the placebo run-in) to week 4 (2 weeks of rilonacept) (5.0 to 2.8; p<0.049), with sustained improvement at week 8 (1.3; p<0.049); 5 of 10 patients reported at least a 75% improvement. Median symptom-adjusted and severity-adjusted joint scores were significantly decreased. High-sensitivity C-reactive protein levels fell significantly.

Conclusions: This proof-of-concept study demonstrated that rilonacept is generally well tolerated and may offer therapeutic benefit in reducing pain in patients with chronic refractory gouty arthritis, supporting the need for larger, randomised, controlled studies of IL1 antagonism such as with rilonacept for this clinical indication.

Footnotes

  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

  • Ethics approval Approved by the institutional review board at each site.

  • ▸ Additional text and figures are published online only at http://ard.bmj.com/content/vol68/issue10